Swine Vaccines Market Size Report By 2030

The global Swine Vaccines market size is expected to be worth around US$ 6.5 billion by 2030, according to a new report by Vision Research Reports.

The global Swine Vaccines market size was valued at US$ 2.45 billion in 2020 and is anticipated to grow at a CAGR of 5.9% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39081

Growth Factors

Increasing prevalence of diseases, a surge in the demand for animal protein, and growth in R&D expenditure for vaccines innovation are driving the market growth. Porcine Parvovirus (PPV), Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine circovirus type 2 (PCV2), Foot & Mouth Disease, Classical Swine Fever, and others remain to be extremely prevalent diseases in pig farms affecting economic losses.

Swine production is a key component of global food security, agricultural countries, and local & international business. Contagious diseases impact pig health and stability and productivity of the swine industry globally. Thus, the rising prevalence of diseases in swine is estimated to drive the market over the forecast years. Porcine Parvovirus (PPV) is a reproductive disease present in most pig farms globally. Porcine Reproductive and Respiratory Syndrome (PRRS) remains to be a highly prevalent disease in pig farms affecting economic losses through its adverse effects on reproduction and growth as well as by clinical illness.

Report Coverage

Report Scope Details
Market Size US$ 6.5 billion by 2030
Growth Rate CAGR of 5.9% From 2021 to 2030
Largest Market Asia Pacific
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Product, Type
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Merck Animal Health; Ceva; Zoetis; BoehringerIngelheim GmbH; Elanco; Indian Immunologicals Ltd.; BiogénesisBagó; Phibro Animal Health; KM Biologics; HIPRA

By Product Analysis

The inactivated vaccines segment dominated the global market in 2020 with a revenue share of more than 38% in 2020. This is attributed to the easy availability, low cost, minimal risk of revert reaction of killed viruses, and new improvements by key players.

The recombinant vaccine segment is expected to exhibit the fastest CAGR from 2021 to 2028. These vaccines are anticipated to assist in achieving vaccination against several virus strains, as recombinants can carry numerous gene inserts.

By Type Analysis

The Porcine Circovirus type 2 (PCV2) dominated the global market with a revenue share of more than 14% in 2020. Transmission of PCV-2 may be by direct contact with an infected pig. PCV2 is the quickly mutating of all single-stranded DNA (ssDNA) viruses and thus, has a great mutation and recombination rate.

The foot & mouth disease segment is expected to witness the second-fastest CAGR over the forecast period. In swine, foot-and-mouth disease is an epidemic that has a substantial effect on food safety and animal husbandry.

By Regional Analysis

Asia Pacific accounted for the maximum revenue share of more than 46% in 2020 and is anticipated to register the fastest CAGR during the forecast period. Middle-income nations, especially Southeast Asian countries, consume greater amounts of meat and the meat consumption of pork is still on the rise.

North America held a significant revenue share in 2020. The presence of well-established veterinary healthcare infrastructure, increased demand for animal protein, highly organized farming structure, and rising expenditure on animal health is attributed to the region’s growth.

Key Players

  • Merck Animal Health
  • Ceva
  • Zoetis
  • Boehringer Ingelheim GmbH
  • Elanco
  • Indian Immunologicals Ltd.
  • BiogénesisBagó
  • Phibro Animal Health
  • KM Biologics
  • HIPRA

Market Segmentation

  • By Type
    • Swine Influenza
    • Classical Swine Fever
    • Porcine Parvovirus
    • Porcine Circovirus Type 2
    • M.Hyo
    • ActinobacillusPleuropneumonia
    • PRRS
    • Foot & Mouth Disease
    • Pseudorabies
    • PEDV
    • Others
  • By Product
    • Attenuated Live Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • DNA Vaccines
    • Recombinant Vaccines
  • Regional
    • North America
      • U.S.
      • Canada
    •  Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East and Africa (MEA)
      • Saudi Arabia
      • South Africa

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Swine Vaccines Market, By Type

7.1.  Swine Vaccines Market, by Type, 2021-2030

7.1.1.    Swine Influenza

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Classical Swine Fever

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Porcine Parvovirus

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Porcine Circovirus Type 2

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    M.Hyo

7.1.5.1.        Market Revenue and Forecast (2017-2030)

7.1.6.    ActinobacillusPleuropneumonia

7.1.6.1.        Market Revenue and Forecast (2017-2030)

7.1.7.    PRRS

7.1.7.1.        Market Revenue and Forecast (2017-2030)

7.1.8.    Foot & Mouth Disease

7.1.8.1.        Market Revenue and Forecast (2017-2030)

7.1.9.    Pseudorabies

7.1.9.1.        Market Revenue and Forecast (2017-2030)

7.1.10.  PEDV

7.1.10.1.      Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Swine Vaccines Market, By Product

8.1.  Swine Vaccines Market, by Product, 2021-2030

8.1.1.    Attenuated Live Vaccines

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Inactivated Vaccines

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Subunit Vaccines

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    DNA Vaccines

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Recombinant Vaccines

8.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Swine Vaccines Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Type (2017-2030)

9.1.2.    Market Revenue and Forecast, by Product (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Type (2017-2030)

9.2.2.    Market Revenue and Forecast, by Product (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Type (2017-2030)

9.3.2.    Market Revenue and Forecast, by Product (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Type (2017-2030)

9.4.2.    Market Revenue and Forecast, by Product (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Product (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Type (2017-2030)

9.5.2.    Market Revenue and Forecast, by Product (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Product (2017-2030)

Chapter 10.  Company Profiles

10.1.              Merck Animal Health

10.1.1.  Company Overview

10.1.2.  Type Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Ceva

10.2.1.  Company Overview

10.2.2.  Type Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Zoetis

10.3.1.  Company Overview

10.3.2.  Type Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Boehringer Ingelheim GmbH

10.4.1.  Company Overview

10.4.2.  Type Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Elanco

10.5.1.  Company Overview

10.5.2.  Type Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Indian Immunologicals Ltd.

10.6.1.  Company Overview

10.6.2.  Type Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              BiogénesisBagó

10.7.1.  Company Overview

10.7.2.  Type Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Phibro Animal Health

10.8.1.  Company Overview

10.8.2.  Type Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              KM Biologics

10.9.1.  Company Overview

10.9.2.  Type Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           HIPRA

10.10.1.               Company Overview

10.10.2.               Type Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39081

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Leave a Reply

Your email address will not be published. Required fields are marked *